Twist Bioscience 8-K
Equity raise
Upsized stock offering to fund R&D, manufacturing capacity and product offerings; underwriters exercised their option in full.
Filed 2026-08-05 17:27 ET
- 1.01 Entry into a Material Agreement
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Twist Bioscience’s upsized public common-stock offering. The company priced 3.125 million shares at $96 each and the underwriters exercised their option in full for another 468,750 shares. Proceeds are intended to fund research and development, manufacturing capacity and product offerings, with the remainder for working capital and general corporate purposes.
Key Figures
- Offering: 3.125 million shares at $96 per share; gross proceeds of $300 million before discounts, commissions and expenses, up from the proposed $250 million.
- Underwriters exercised the full 30-day option for 468,750 additional shares at $96 per share, less discounts and commissions.
- Net proceeds, including the option shares, are expected to be approximately $327.1 million.
Investor Takeaways
- Closing is expected on or about 8/6/2026, subject to customary conditions.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3